East Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 million


The FDA rejected the company's migraine patch twice, and a biopharma investing downturn made it difficult to raise more money.

Previous Athersys plans reverse stock split by Monday's market opening
Next As Idaho abortion ban to take effect, leaders vow to support those seeking services in Oregon